To produce Provenge®, the patient's leukocytes are collected and then expanded ex vivo with a prostate cancer tissue antigen (prostatic acid phosphatase [PAP]) and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). The gene discussed is ACP3; the disease is prostate carcinoma.